JPMORGAN CHASE & CO - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 90 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$837,184
-42.9%
709,478
-31.8%
0.00%
Q2 2023$1,467,086
-12.0%
1,040,487
-6.4%
0.00%
Q1 2023$1,668,000
+130826.2%
1,112,111
+2.2%
0.00%
Q4 2022$1,274
-99.9%
1,088,579
+3.8%
0.00%
Q3 2022$1,185,000
-40.3%
1,049,051
-16.5%
0.00%
Q2 2022$1,986,000
-30.3%
1,256,932
-32.0%
0.00%
Q1 2022$2,849,000
-9.4%
1,849,662
+44.1%
0.00%
Q4 2021$3,145,000
-43.7%
1,283,277
-42.1%
0.00%
-100.0%
Q3 2021$5,584,000
+0.4%
2,215,792
+13.5%
0.00%0.0%
Q2 2021$5,564,0001,952,108
+2674020.5%
0.00%
Q1 2021$0
-100.0%
73
-96.8%
0.00%
Q4 2020$4,000
-66.7%
2,262
-82.0%
0.00%
Q3 2020$12,000
+140.0%
12,544
+126.6%
0.00%
Q2 2020$5,000
-96.6%
5,536
-96.9%
0.00%
Q1 2020$148,000
+16.5%
178,846
+26.1%
0.00%
Q4 2019$127,000
+262.9%
141,846
+300.1%
0.00%
Q3 2019$35,00035,4560.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q4 2020
NameSharesValueWeighting ↓
Defender Capital, LLC. 4,735,990$8,335,0003.63%
BROADWOOD CAPITAL INC 34,005,379$59,849,0003.55%
Prescott General Partners LLC 1,851,851$3,259,0000.14%
Strategic Wealth Investment Group, LLC 66,917$118,0000.07%
Laidlaw Wealth Management LLC 170,658$300,0000.06%
Humankind Investments LLC 26,737$47,0000.05%
DAFNA Capital Management LLC 80,000$141,0000.04%
Beirne Wealth Consulting Services, LLC 45,000$79,0000.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 680,839$1,198,0000.02%
Allegheny Financial Group LTD 20,000$35,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders